Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety
I'm LongbridgeAI, I can summarize articles.Cybin's Helus Pharma announced promising Phase 2 results for its investigational drug HLP004, targeting adults with moderate-to-severe generalized anxiety disorder. In a study of 36 patients, those receiving 20 mg of HLP004 showed a significant reduction in anxiety symptoms compared to placebo. The treatment demonstrated a durable effect, with 67% of patients responding positively at six months. This positions HLP004 as a potential adjunctive therapy in a market lacking approved options. Analysts rate Cybin's stock (HELP) as a Buy, with a target price of $95.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Cybin ( (HELP) ).
On March 5, 2026, Helus Pharma reported topline Phase 2 signal detection results for its investigational NSA HLP004 in adults with moderate-to-severe generalized anxiety disorder who remained symptomatic despite standard antidepressant therapy. The study randomized 36 patients to two intramuscular doses of HLP004 or placebo, delivered three weeks apart, on top of ongoing standard of care.
Patients receiving 20 mg HLP004 achieved a statistically significant and clinically meaningful mean reduction of 10.4 points on the Hamilton Anxiety Rating Scale at six weeks, over and above standard treatments, in a difficult-to-treat population. The effect appeared durable, with pooled data showing 67% responders and 39% remitters at six months, alongside a short, commercially scalable in-clinic experience of about 90 minutes of acute effects and discharge readiness within roughly three hours, and a favorable tolerability profile without drug-related serious adverse events.
These data position HLP004 as a promising adjunctive option in a GAD market where roughly half of patients fail first-line therapy and no adjunctive drug has been approved, underscoring Helus Pharma’s bid to strengthen its footprint in interventional psychiatry. The strong signal in anxiety, combined with the company’s advanced depression program HLP003, may enhance Cybin’s standing among investors and clinicians focused on next-generation serotonergic treatments for refractory mental health disorders.
The most recent analyst rating on (HELP) stock is a Buy with a $95.00 price target. To see the full list of analyst forecasts on Cybin stock, see the HELP Stock Forecast page.
More about Cybin
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) to treat serious mental health conditions such as depression and anxiety. Its pipeline includes HLP003 in Phase 3 for adjunctive treatment of major depressive disorder, which has U.S. FDA Breakthrough Therapy Designation, and HLP004 in Phase 2 for generalized anxiety disorder, supported by an extensive NSA research portfolio across North America and Europe.
Average Trading Volume: 666,724
Technical Sentiment Signal: Hold
Current Market Cap: $1.4M
Learn more about HELP stock on TipRanks’ Stock Analysis page.